346 related articles for article (PubMed ID: 30293230)
1. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
Martínez N; Herrera M; Frías L; Provencio M; Pérez-Carrión R; Díaz V; Morse M; Crespo MC
Clin Transl Oncol; 2019 Apr; 21(4):489-498. PubMed ID: 30293230
[TBL] [Abstract][Full Text] [Related]
2. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
Hershman DL; Unger JM; Crew KD; Awad D; Dakhil SR; Gralow J; Greenlee H; Lew DL; Minasian LM; Till C; Wade JL; Meyskens FL; Moinpour CM
J Clin Oncol; 2015 Jun; 33(17):1910-7. PubMed ID: 25940724
[TBL] [Abstract][Full Text] [Related]
3. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.
Lustberg MB; Orchard TS; Reinbolt R; Andridge R; Pan X; Belury M; Cole R; Logan A; Layman R; Ramaswamy B; Wesolowski R; Berger M; Patterson E; Loprinzi C; Shapiro CL; Yee L
Breast Cancer Res Treat; 2018 Feb; 167(3):709-718. PubMed ID: 29101597
[TBL] [Abstract][Full Text] [Related]
4. Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
Bhave MA; Speth KA; Kidwell KM; Lyden A; Alsamarraie C; Murphy SL; Henry NL
Clin Breast Cancer; 2018 Apr; 18(2):168-174.e2. PubMed ID: 29361424
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms.
Helzlsouer KJ; Gallicchio L; MacDonald R; Wood B; Rushovich E
Breast Cancer Res Treat; 2012 Jan; 131(1):277-85. PubMed ID: 21904883
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
Crew KD; Capodice JL; Greenlee H; Apollo A; Jacobson JS; Raptis G; Blozie K; Sierra A; Hershman DL
J Cancer Surviv; 2007 Dec; 1(4):283-91. PubMed ID: 18648963
[TBL] [Abstract][Full Text] [Related]
7. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
Khan QJ; Kimler BF; Reddy PS; Sharma P; Klemp JR; Nydegger JL; Yeh HW; Fabian CJ
Breast Cancer Res Treat; 2017 Nov; 166(2):491-500. PubMed ID: 28770449
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor-Associated Musculoskeletal Symptoms.
Henry NL; Unger JM; Till C; Crew KD; Fisch MJ; Hershman DL
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34901744
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
Shen S; Unger JM; Crew KD; Till C; Greenlee H; Gralow J; Dakhil SR; Minasian LM; Wade JL; Fisch MJ; Henry NL; Hershman DL
Breast Cancer Res Treat; 2018 Dec; 172(3):603-610. PubMed ID: 30159789
[TBL] [Abstract][Full Text] [Related]
11. Effects of the Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: A randomized, controlled clinical trial.
Peng N; Yu M; Yang G; Fu Q; Xu Y; Yu J; Liu Q; Li C; Xu W; Zhang Y; Ma C; Yang L; Yu R; Wang X
Breast; 2018 Feb; 37():18-27. PubMed ID: 29059538
[TBL] [Abstract][Full Text] [Related]
12. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.
Bao T; Cai L; Giles JT; Gould J; Tarpinian K; Betts K; Medeiros M; Jeter S; Tait N; Chumsri S; Armstrong DK; Tan M; Folkerd E; Dowsett M; Singh H; Tkaczuk K; Stearns V
Breast Cancer Res Treat; 2013 Feb; 138(1):167-74. PubMed ID: 23393007
[TBL] [Abstract][Full Text] [Related]
13. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
[TBL] [Abstract][Full Text] [Related]
14. A Novel Combination of ω-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study.
Abdolahi M; Sarraf P; Javanbakht MH; Honarvar NM; Hatami M; Soveyd N; Tafakhori A; Sedighiyan M; Djalali M; Jafarieh A; Masoudian Y; Djalali M
CNS Neurol Disord Drug Targets; 2018; 17(6):430-438. PubMed ID: 29938621
[TBL] [Abstract][Full Text] [Related]
15. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Hack CC; Häberle L; Brucker SY; Janni W; Volz B; Loehberg CR; Hartkopf AD; Walter CB; Baake G; Fridman A; Malter W; Wuerstlein R; Harbeck N; Hoffmann O; Kuemmel S; Martin B; Thomssen C; Graf H; Wolf C; Lux MP; Bayer CM; Rauh C; Almstedt K; Gass P; Heindl F; Brodkorb T; Willer L; Lindner C; Kolberg HC; Krabisch P; Weigel M; Steinfeld-Birg D; Kohls A; Brucker C; Schulz V; Fischer G; Pelzer V; Rack B; Beckmann MW; Fehm T; Rody A; Maass N; Hein A; Fasching PA; Nabieva N
Breast; 2020 Apr; 50():11-18. PubMed ID: 31958661
[TBL] [Abstract][Full Text] [Related]
16. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
[TBL] [Abstract][Full Text] [Related]
17. Omega-3 Fatty Acids for Aromatase Inhibitor-Induced Musculoskeletal Pain: Anything Other Than a Placebo Effect?
Gianni L; Arcangeli V; Tamburini E; Tassinari D
J Clin Oncol; 2015 Dec; 33(36):4311-2. PubMed ID: 26392100
[No Abstract] [Full Text] [Related]
18. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.
Singer O; Cigler T; Moore AB; Levine AB; Hentel K; Belfi L; Do HT; Mandl LA
Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1910-8. PubMed ID: 22730307
[TBL] [Abstract][Full Text] [Related]
19. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
